MartÃnez-Vila, C.; Teixido, C.; MartÃn, R.; Aya, F.; Sudhaman, S.; Budde, G.L.; González-Navarro, E.A.; Alos, L.; Castrejon, N.; Ortiz, J.B.;
et al. Personalized Circulating Tumor DNA Assay to Assess Long-Term Clinical Benefit in Patients with Advanced Melanoma. Cancers 2025, 17, 3804.
https://doi.org/10.3390/cancers17233804
AMA Style
MartÃnez-Vila C, Teixido C, MartÃn R, Aya F, Sudhaman S, Budde GL, González-Navarro EA, Alos L, Castrejon N, Ortiz JB,
et al. Personalized Circulating Tumor DNA Assay to Assess Long-Term Clinical Benefit in Patients with Advanced Melanoma. Cancers. 2025; 17(23):3804.
https://doi.org/10.3390/cancers17233804
Chicago/Turabian Style
MartÃnez-Vila, Clara, Cristina Teixido, Roberto MartÃn, Francisco Aya, Sumedha Sudhaman, Griffin L. Budde, Europa Azucena González-Navarro, Llucia Alos, Natalia Castrejon, J. Bryce Ortiz,
and et al. 2025. "Personalized Circulating Tumor DNA Assay to Assess Long-Term Clinical Benefit in Patients with Advanced Melanoma" Cancers 17, no. 23: 3804.
https://doi.org/10.3390/cancers17233804
APA Style
MartÃnez-Vila, C., Teixido, C., MartÃn, R., Aya, F., Sudhaman, S., Budde, G. L., González-Navarro, E. A., Alos, L., Castrejon, N., Ortiz, J. B., Krainock, M., Liu, M. C., & Arance, A.
(2025). Personalized Circulating Tumor DNA Assay to Assess Long-Term Clinical Benefit in Patients with Advanced Melanoma. Cancers, 17(23), 3804.
https://doi.org/10.3390/cancers17233804
